Pacritinib hydrochloride

Modify Date: 2024-01-14 08:36:53

Pacritinib hydrochloride Structure
Pacritinib hydrochloride structure
Common Name Pacritinib hydrochloride
CAS Number 1228923-43-0 Molecular Weight N/A
Density N/A Boiling Point N/A
Molecular Formula C28H32N4O3.xClH Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Pacritinib hydrochloride


Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3].

 Names

Name Pacritinib hydrochloride

 Pacritinib hydrochloride Biological Activity

Description Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3].
Related Catalog
Target

JAK2V617F:19 nM (IC50)

JAK3:520 nM (IC50)

JAK1:1280 nM (IC50)

JAK2wt:23 nM (IC50)

Tyk2:50 nM (IC50)

References

[1]. Hart S, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011 Nov;25(11):1751-9.

[2]. Hart S, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011 Nov;1(11):e44.

[3]. Komrokji RS, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55.

 Chemical & Physical Properties

Molecular Formula C28H32N4O3.xClH
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.